Top Page
Alphamab Oncology
(9966)
Alphamab Oncology (9966) vs. iShares MSCI Hong Kong ETF (EWH)
Alphamab Oncology Business Overview & Revenue Model
Alphamab Oncology Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 640.08M | 218.77M | 166.84M | 146.02M | 0.00 |
| Gross Profit | 579.77M | 163.54M | 122.64M | 142.99M | 0.00 |
| EBITDA | 156.79M | -129.30M | -391.83M | -358.13M | -390.47M |
| Net Income | 166.34M | -210.59M | -325.72M | -412.42M | -427.77M |
Balance Sheet | |||||
| Total Assets | 2.24B | 2.14B | 2.12B | 2.71B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.57B | 1.41B | 1.35B | 1.99B | 2.06B |
| Total Debt | 185.96M | 257.08M | 345.39M | 637.27M | 222.81M |
| Total Liabilities | 409.87M | 465.00M | 559.86M | 834.80M | 366.44M |
| Stockholders Equity | 1.83B | 1.67B | 1.56B | 1.87B | 2.27B |
Cash Flow | |||||
| Free Cash Flow | 190.56M | -239.02M | -429.96M | -478.72M | -438.00M |
| Operating Cash Flow | 212.34M | -202.84M | -300.31M | -320.60M | -347.18M |
| Investing Cash Flow | -92.93M | -18.11M | 850.76M | 574.26M | -1.52B |
| Financing Cash Flow | -98.96M | 218.07M | -310.90M | 363.90M | 186.58M |
Alphamab Oncology Technical Analysis
Alphamab Oncology Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$6.53B | 165.93 | 1.43% | ― | 2433.62% | ― | |
59 Neutral | HK$15.54B | 5.61 | -7.44% | 4.07% | 11.55% | -28.15% | |
57 Neutral | HK$8.62B | ― | -13.97% | ― | -97.81% | -117.20% | |
51 Neutral | HK$6.35B | 34.91 | 9.52% | ― | 185.36% | ― | |
51 Neutral | HK$8.93B | ― | -51.40% | ― | 58.75% | -1310.16% | |
50 Neutral | HK$2.29B | ― | -75.64% | ― | 42.21% | 29.52% | |
46 Neutral | HK$6.62B | 274.48 | 2.28% | ― | -57.55% | -87.49% |
Alphamab Oncology Corporate Events
Alphamab Oncology has established a Nomination Committee to enhance its corporate governance structure. The committee will be responsible for reviewing the board’s composition, identifying qualified candidates for directorships, and ensuring board diversity. This move is expected to strengthen the company’s strategic direction and improve stakeholder confidence.
Alphamab Oncology announced changes in its board of directors, with the resignation of Dr. Guo Zijian and Mr. Wei Kevin Cheng as independent non-executive directors, effective June 30, 2025, due to personal and work commitments. The company has appointed Ms. Wong Yan Ki Angel and Dr. Gao Xiang as new independent non-executive directors, bringing extensive experience in accounting, corporate finance, and capital markets, which could positively impact Alphamab’s strategic direction and governance.
Alphamab Oncology announced that all proposed resolutions at their Annual General Meeting on June 12, 2025, were approved by shareholders. Key resolutions included the approval of financial statements, granting mandates for share repurchase and issuance, and the re-election of directors, indicating strong shareholder support and potentially enhancing the company’s strategic flexibility and governance.
Alphamab Oncology announced the completion of a share placing by its controlling shareholder, involving 14,600,000 shares, which represents approximately 1.51% of the company’s issued share capital. This transaction, executed at HK$8.05 per share, adjusts the shareholding distribution, with the Vendor now holding 31.0% of shares. This move is likely to impact the company’s market positioning and shareholder dynamics.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced research updates for its drug JSKN003, presented at the 2025 ASCO Annual Meeting. The updates highlight the drug’s efficacy and safety in treating advanced solid tumors, including platinum-resistant ovarian cancer and heavily pretreated HER2-positive breast cancer. The studies show promising results, with significant tumor shrinkage and manageable safety profiles, positioning JSKN003 as a potential treatment option in ongoing phase III trials.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its controlling shareholder, Rubymab Ltd., has entered into a share placing agreement with Morgan Stanley & Co. International plc to sell 14,600,000 existing shares, representing approximately 1.51% of the company’s total issued share capital. This transaction is expected to slightly reduce Rubymab Ltd.’s stake in the company from 32.5% to 31.0%, potentially impacting the company’s shareholder structure and market perception.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced the grant of 120,000 award shares under its Restricted Share Award Scheme to three directors, including one non-executive and two independent non-executive directors. This move is part of the company’s strategy to reward the directors for their contributions and align their interests with the company’s goals. The shares will vest over 24 months and do not have performance targets, which the Remuneration Committee believes is consistent with market practices and the company’s remuneration policy.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced its upcoming Annual General Meeting scheduled for June 12, 2025, in Suzhou, China. The meeting will address several key resolutions, including the approval of financial statements and the authorization for directors to repurchase shares and issue additional shares. These resolutions are expected to impact the company’s operational strategies and shareholder value, reflecting its commitment to maintaining a strong market position and enhancing shareholder returns.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its pivotal Phase II/III clinical trial of KN026, a next-generation HER2-targeted therapy, has met its primary endpoint of progression-free survival (PFS) in patients with HER2-positive gastric cancer. The trial results indicate a significant improvement in PFS when KN026 is combined with chemotherapy, suggesting potential benefits over current standard treatments. This advancement could enhance Alphamab’s position in the oncology market and provide new treatment options for patients with advanced cancer.
Alphamab Oncology announced the presentation of research updates on their preclinical activities for JSKN021 and JSKN022 at the 2025 AACR Annual Meeting. JSKN021, a dual payload ADC targeting EGFR/HER3, demonstrated strong tumor inhibition and stability in preclinical studies, showing potential to overcome resistance in cancer treatments. JSKN022, targeting PD-L1 and ITGB6/8, exhibited enhanced tumor suppression and stability, indicating its promise as a multi-specific ADC for cancer therapy. These advancements highlight Alphamab’s commitment to developing next-generation cancer treatments with improved efficacy and reduced toxicity.
Alphamab Oncology announced the grant of share options under its Post-IPO Share Option Scheme and award shares under the Restricted Share Award Scheme to eligible employees. This initiative is part of the company’s strategy to incentivize and retain talent, aligning employee interests with company performance and potentially enhancing its competitive positioning in the oncology sector.